Cargando…
Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose
Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD), but it increases infection risk and impairs vaccine responses. Herein we evaluated the antibody response of RTX-treated patients to the supplemental COVID-19 vaccine. After the supplemental dose, 53.1% of patient...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547394/ https://www.ncbi.nlm.nih.gov/pubmed/36220613 http://dx.doi.org/10.1016/j.clim.2022.109144 |